Background
Rheumatoid arthritis (RA) is a progressive, destructive, lifelong condition 1, 2 associated with significant co-morbidity, which causes significant reduction of life expectancy 3 and quality of life. 1, 2 Its prevalence is estimated to be 0.76-1.00% in the adult population, with an incidence of 0.06% [1] [2] [3] and female patients with RA outnumbering men at a ratio of 2.3:1. [1] [2] [3] As new medications enter the market for RA, economic evaluations provide critical information for assessing cost-effectiveness.
Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.
In Canada, tofacitinib in combination with methotrexate is indicated for reducing the signs and symptoms of RA in adult patients with moderately to severely active RA who have had an inadequate response to methotrexate. In cases of intolerance to methotrexate, physicians may consider the use of tofacitinib as monotherapy. 4 The objective of this analysis was to estimate the costs and effects, including incremental cost-effectiveness ratios (ICER), of tofacitinib compared with the currently available products for the management of moderate to severe RA post-failure with traditional disease-modifying antirheumatic drugs, from the Canadian healthcare perspective.
Methods

Model design
A patient-level microsimulation model with a 6-month cycle length was used to estimate the lifetime costs and quality-adjusted life-years (QALY) associated with RA treatment and disease progression.
The model compared a treatment sequence with tofacitinib with a comparator sequence without tofacitinib in the patient care pathway following the 2012 Canadian Rheumatology Association recommendations for the pharmacologic management of RA. 5 Tofacitinib was included in the treatment algorithm in a position similar to the tumor necrosis factor inhibitors (Table 1) .
Costs included in the analysis were drugs and healthcare resource utilizations and were estimated in 2014 Canadian dollars (Table 2 ).
Efficacy was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) score and HAQ-DI score change for each 6-month cycle of the model. The HAQ-DI score for a patient in a cycle is based on their HAQ-DI score in the previous cycle and the change in HAQ-DI score in the current model cycle.
The HAQ-DI score change for any specific medication was divided into short-term changes (6 months post-treatment initiation), medium-term changes (between 6-36 months post-treatment initiation), and long-term changes (>36 months post-treatment initiation; Figure 1 ).
Data for HAQ-DI change during the first 6 months of treatment was based on a network meta-analysis for the effectiveness of different treatments for moderately to severely active RA. 6 Data on medium-term HAQ-DI score changes were derived from various sources, including long-term extension trials. 7 Because of lack of data, a mean long-term HAQ-DI change of 0 was assumed for all medications.
In each 6-month cycle, patients could suffer an adverse event that resulted in increased costs and decreased utility in the cycle in which the adverse event occurred. Identified serious adverse events were serious infections (pneumonia), herpes zoster, and opportunistic infection (tuberculosis). Utility (as measured by the EuroQol five-dimension instrument) was estimated from a published algorithm, which estimated the relationship between HAQ-DI score and Health Utilities Index Mark 2 and Mark 3. 8 During each cycle of the model, patients accrued non-medication healthcare resource costs that were dependent on their current HAQ-DI score taken from a published Canadian study of the costs of patients with RA (Table 3 ; Figure 2 ). 9 Disutility of using subcutaneous injection or intravenous infusion was integrated for relevant comparators.
Each patient simulated through the model was assigned a starting value for HAQ-DI score, age, weight, and duration of RA, as shown in Table 4 .
Results
After running the model for 100,000 simulations of patients with moderate to severe RA, the treatment arm including tofacitinib had lifetime costs of $298,669 with 8.18 QALYs. Comparatively, the treatment arm excluding tofacitinib had a lifetime cost of $305,441 with 7.88 QALYs. Therefore, a treatment strategy including tofacitinib was shown to be dominant with lower costs and greater effectiveness (Table 5) .
One-way sensitivity analysis (Table 6 ) demonstrates the robustness of the results, with all cases showing the inclusion of tofacitinib to the treatment algorithm to be dominant to the treatment algorithm that does not include tofacitinib.
Probabilistic sensitivity analysis (Figures 3 and 4) was also completed showing that more than 76.7% of all results have an ICER <$50,000 per QALY.
Conclusions
This Canadian-specific model, integrating baseline characteristics for patients with RA, medication costs, estimates of non-medication healthcare resource costs by HAQ-DI score range and for the HAQ-DI-to-utility relationship equation that were taken from Canadian source, shows that the inclusion of tofacitinib into the treatment strategy for moderate to severe RA is a dominant strategy (lower cost and increased QALYs).
These results were shown to be robust after completing one-way and probabilistic sensitivity analyses.
A strength of this model was in its ability to evaluate different sequences of treatments.
A limitation of this approach was that the clinical data used in the model was taken from network metaanalysis results and was not from head-to-head trials and, therefore, did not account for previous failure from the specific treatments in the proposed paradigm. 
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